Cognito Therapeutics, Inc.

Cognito Therapeutics is a privately held neurotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. Headquartered in Cambridge, Massachusetts, the company's mission is to improve the lives of patients by pioneering innovative, technology-based therapeutic interventions.

The company's lead product is the Spectris™ platform, an investigational at-home therapeutic device. Spectris utilizes non-invasive, sensory-driven neurostimulation (visual and auditory) to evoke specific brain wave activity, particularly gamma oscillations, which are disrupted in neurodegenerative conditions like Alzheimer's. The therapy aims to preserve brain structure, cognition, and daily function in patients with mild-to-moderate Alzheimer's disease. Spectris has received FDA Breakthrough Device Designation, and Cognito Therapeutics is also exploring its application for other neurodegenerative indications.

In March 2026, Cognito Therapeutics announced the final close of an oversubscribed $105 million Series C funding round, led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital. The funding is intended to advance the pivotal HOPE study, support regulatory submission, and prepare for the anticipated commercial launch of Spectris in 2027. Christian Howell serves as the Chief Executive Officer, leading a team that includes Ralph Kern as Chief Medical Officer and Head of R&D, Steve Worthy as Chief Business & Financial Officer, and Robbert Zusterzeel as Chief Clinical & Regulatory Officer.